Gallbladder bile tumor marker quantification for detection of pancreato-biliary malignancies

Anticancer Research

Volumn 20, Issue 6 D, 2000, Pages 4941-4947

  Brockmann, J ^a   Emparan, C ^a   Hernandez, C A ^a   Sulkowski, U ^a   Dietl, K H ^a   Menzel, J ^a   Wolters, H ^a   Glodny, B ^a   Senninger, N ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Bile; Pancreato biliary carcinoma; Tumor marker analysis

Indexed keywords

ALPHA FETOPROTEIN; BILE ACID; CA 125 ANTIGEN; CA 19-9 ANTIGEN; CA 72-4 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; TUMOR MARKER;

ANTIGEN DETECTION; BILE DUCT CANCER; BILE LEVEL; BILIARY TRACT SURGERY; CANCER DIAGNOSIS; CONFERENCE PAPER; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ENTEROHEPATIC CIRCULATION; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PANCREAS CANCER; PANCREAS JUICE; PANCREATITIS; PRIORITY JOURNAL; TUMOR DIFFERENTIATION; VALIDATION PROCESS; VATER PAPILLA;

ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; BILE DUCTS; BILIARY TRACT NEOPLASMS; CA-125 ANTIGEN; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; GALLBLADDER; HUMANS; PANCREATIC NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0034451480     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (23)

1. Comparison of the sensitivity and specificity of the CA 19-9 and carcinogenic antigen assays in detecting cancer of the pancreas
2. The prognostic value of preoperative serum values of CA 19-9 and CEA in patients with pancreatic cancer
3. Prognostic value of serum CA 19-9 levels in pancreatic adenocarcinoma
4. Tumor antigens CA 195 and CA 19-9 in pancreatic juice and serum for the diagnosis of pancreatic carcinoma
5. Diagnostic significance of cancer-associated carbohydrate antigen (CA 19-9) concentrations in pancreatic juice: Analysis in pure pancreatic juice collected by endoscopic aspiration and immunohistochemical study in chronic pancreatitis
6. Values of CA 19-9 in serum, pure pancreatic juice, and aspirated pancreatic material in the diagnosis of malignant pancreatic tumor
7. Evaluation of cytology and tumor markers of pure pancreatic juice for the diagnosis of pancreatic cancer at early stages
8. Determination of CA 19-9 antigen in serum and pancreatic juice for differential diagnosis of pancreatic adenocarcinoma from chronic pancreatitis
9. Pancreatic juice 90K and serum CA 19-9 combined determination can discriminate between pancreatic cancer and chronic pancreatitis
10. Comperative studies of DU-PAN-2, carcinoembryonic antigen, and CA 19-9 in the serum and bile of patients with pancreatic and biliary tract diseases: Evaluation of the influence of obstructive jaundice
11. A monoclponal antibody-defined antigen associated with gastrointestinal cancer is a ganglioside containing sialylated lacto-N-fucopentoase II
12. Prognostic value of serum CA 19-9 levels in pancreatic adenocarcinoma
13. Cancer-associated tumor markers CA 19-9 and CA-50 in patients with pancreatic cancer with special reference to the Lewis blood cell status
14. Measurement of a monoclonal-antibody-defined antigen (CA19-9) in the sera of patients with malignant and nonmalignant diseases. Comparison with carcinoembryonic antigen
15. Elevated tumor-associated antigen CA 19-9 in a patient with an enlarged Pancreas: Does it always imply malignancy?
16. Elevated serum levels of tumor marker CA 19-9 in acute cholangitis
17. Excessive CA 19-9-Erhöhung. Eine konstellation mit klinischer symptomatik ohne malignomnachwies
18. Comperative studies on immunoglobins, complement component (C3), albumin, and immunoglobin A-containing circulating immune complexes in serum and bile of patients with biliary obstruction
19. Effects of percutaneous transhepatic biliary drainage on blood-bile permeability and selective IgA transport in patients with biliary obstruction
20. Comparative study of CA 242 and CA 19-9 in chronic pancreatitis
21. Evaluation of CA 19-9 as a serum tumor marker in pancreatic cancer
22. Assessment of serum and bile levels of CA 19-9 and CA 125 in cholangitis and bile duct carcinoma
23. CA 19-and pancreatic adenocarcinoma